Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common shares
-
Shares outstanding
-
250,425,788
-
Total 13F shares
-
109,349,495
-
Share change
-
+2,237,919
-
Total reported value
-
$49,687,946
-
Put/Call ratio
-
38%
-
Price per share
-
$0.45
-
Number of holders
-
126
-
Value change
-
+$369,638
-
Number of buys
-
55
-
Number of sells
-
35
Institutional Holders of Lineage Cell Therapeutics, Inc. - Common shares (LCTX) as of Q1 2025
As of 31 Mar 2025,
Lineage Cell Therapeutics, Inc. - Common shares (LCTX) was held by
126 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
109,349,495 shares.
The largest 10 holders included
BROADWOOD CAPITAL INC, BlackRock, Inc., VANGUARD GROUP INC, Defender Capital, LLC., RAFFLES ASSOCIATES LP, GEODE CAPITAL MANAGEMENT, LLC, COMERICA BANK, STATE STREET CORP, DAFNA Capital Management LLC, and RENAISSANCE TECHNOLOGIES LLC.
This page lists
126
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.